Sami Sabsina wins patent infringement lawsuit against Olive Lifesciences

New Delhi: Sami-Sabinsa Group has announced that it has successfully concluded its Patent Infringement lawsuit against Bangalore based Olive Lifesciences on April 5, 2018. As per the company, the United States District Court in New Jersey entered a judgment awarding Sabinsa over $850,000 in damages, enhanced damages, attorney’s fees, costs, and interest.

On June 8, 2016, Sami-Sabinsa filed suit against Olive for willful infringement of U.S. Patent No. 6,653,327, according to Sabinsa founder Dr Muhammed Majeed. The ’327 Patent protects Sabinsa’s novel methods and formulations for tetra-hydro-curcuminoids (THCs).

Curcumin C3 Reduct is a Registered Trademark and Patented product of Sami-Sabinsa and is protected under U.S. Patent No. 6,653,327, and International Patents. This ingredient provides many of the benefits of Sabinsa’s Curcumin C3 Complex in a colourless, non-staining form.

The judgment concludes that the ’327 Patent is valid, enforceable, and properly issued by the U.S. Patent and Trademark Office. Sabinsa has patents related to THCs in the United States, Europe, Australia, New Zealand, and other locations. In the United States, Sami-Sabinsa has successfully litigated willful infringement of the ’327 patent and has obtained judgments against other infringers.

Sami-Sabinsa has a well-earned reputation for strong enforcement of its intellectual property rights and will continue to pursue all available legal remedies to protect those rights, Dr Majeed stated. “As a pioneer in the industry, Sami-Sabinsa has researched and developed many innovative products used by the nutritional supplement industry,” Dr Majeed added “The success has spawned many imitators, and Sami-Sabinsa will not hesitate to enforce its patents and other intellectual property,” he continued.

“We are very proud of our long-term partnership with Sami-Sabinsa to make sure that its intellectual property is enforced and respected in the industry,” added James H. Hulme, Sabinsa’s counsel. “Sami-Sabinsa can now point to a string of patent victories after this latest judgment,” Mr Hulme said.

As per Sami-Sabinsa, it has pioneered the introduction of several herbal extracts in the U.S. market as an application-oriented manufacturing and marketing company which manufactures herbal extracts and speciality fine chemicals used for nutritional, pharmaceutical, cosmeceutical, and food products.